Product Description

Danilon Equidos Gold is indicated for the treatment of pain and inflammation associated with musculoskeletal conditions in horses and ponies, including osteoarthritic conditions, bursitis, laminitis and soft tissue inflammation. The microencapsulated suxibuzone formulation offers low ulcerogenic potential compared to phenylbutazone — notably, suxibuzone is converted by hepatic metabolism to its active metabolites phenylbutazone and oxyphenbutazone, which are responsible for its therapeutic effects. The yellow granules are presented in individual 3 g sachets, proven to be palatable when mixed into concentrate feed. This is a more concentrated reformulation of the original Danilon Equidos: the active substance per sachet (1.5 g suxibuzone) is unchanged, but the new 3 g sachets replace the original 10 g sachets, meaning no change in therapeutic dose.

For Horses:

Treatment of pain and inflammation associated with musculoskeletal conditions, including osteoarthritic conditions, bursitis, laminitis and soft tissue inflammation

For Ponies:

Treatment of pain and inflammation associated with musculoskeletal conditions, including osteoarthritic conditions, bursitis, laminitis and soft tissue inflammation

Ponies must receive only half the dose rate recommended for horses — see directions for use below

Which Animals Can Use Danilon Equidos Gold 1.5 g Granules?

Danilon Equidos Gold is licensed for use in horses and ponies only. It is not for use in animals intended for human consumption — treated horses may never be slaughtered for human consumption and must have been declared as not intended for human consumption under national horse passport legislation. Use is not recommended during pregnancy or lactation, as safety has not been established in these periods. Additional risk may be involved when used in very young animals (under 12 weeks of age) or in aged animals due to potentially incomplete or impaired hepatic and renal function; dose adjustment and close monitoring are required in these cases. Always use only under the direction of a veterinary surgeon.

Available Strengths & Sizes

Please order the exact pack size as specified on your veterinary prescription.

Note: Not all pack sizes may be marketed. Part sachets must not be used.

Directions for Use

This is a prescription medication — use exactly as directed by your veterinary surgeon. Add the granules to a portion of concentrate feed; the product is accepted by most horses when mixed in this way. Hay fed immediately before or with the product may delay absorption of suxibuzone and delay the onset of clinical effect — it is advisable to avoid feeding hay immediately prior to, or alongside, each dose.

Dose frequency should be reduced to the minimum necessary for a satisfactory clinical response. If no clinical response is evident after 4–5 days, discontinue treatment and reassess the diagnosis. Refer to the dispensing label and package leaflet for full dosing instructions and all species-specific guidance.

Contraindications

Source: SPC Section 4.3

Do not use in animals with renal (kidney) disease

Do not use in animals with hepatic (liver) disease

Do not use in animals with cardiac (heart) disease

Do not use in animals where there is the possibility of gastrointestinal ulceration or bleeding

Do not use in animals where there is evidence of a blood dyscrasia (blood disorder)

Do not use in known cases of hypersensitivity to the active substance suxibuzone or to any of the excipients (tartrazine E102, mannitol, sucrose, povidone K-30, sodium saccharin, ethyl cellulose 20)

Do not use in animals intended for human consumption — treated horses may never be slaughtered for human consumption

Storage & Handling

This veterinary medicinal product does not require any special storage conditions. Shelf life of the product as packaged for sale is 5 years. Keep out of reach of children and animals. Dispose of unused product or waste materials in accordance with local requirements.

Withdrawal period:

Not to be used in animals intended for human consumption. Treated horses may never be slaughtered for human consumption. The horse must have been declared as not intended for human consumption under national horse passport legislation.

Important Warnings

Source: SPC Sections 4.4 & 4.5

Animal precautions:

NSAIDs can cause inhibition of phagocytosis — in inflammatory conditions associated with bacterial infections, appropriate antimicrobial therapy should be instigated alongside treatment

Do not exceed the stated dose or duration of treatment; dosage should be kept to the minimum necessary to alleviate symptoms

During treatment, do not restrict access to water; avoid use in dehydrated, hypovolaemic or hypotensive animals due to increased risk of renal failure

Ponies carry additional risk compared to horses — posology must be adjusted (half the horse dose rate) and patients monitored closely

In very young animals (under 12 weeks) or aged animals, hepatic and renal function may be incomplete or impaired — dose adjustment and close monitoring are required

Part sachets must not be used

In case of overdose, signs may include thirst, depression, anorexia, weight loss, gastrointestinal ulceration and diarrhoea, blood in faeces, altered blood profiles, haemorrhages, hypoproteinaemia with ventral oedema, hypovolaemic shock, circulatory collapse and renal failure — discontinue immediately and initiate symptomatic therapy

Human safety warnings:

Tartrazine (E102) may cause allergic reactions — persons with known sensitivity to tartrazine should take particular care

Persons with known hypersensitivity to suxibuzone or any of the excipients should avoid contact with the product

Wear suitable gloves; wash hands thoroughly after use

Use in a well-ventilated area — avoid inhaling dust when opening sachets and mixing with feed

Avoid contact with skin, eyes and mucous membranes; in case of accidental contact, wash immediately with plenty of clean water

In case of accidental ingestion, seek medical advice immediately and show the label or package leaflet to the physician

Drug interactions:

Do not administer concurrently with other NSAIDs, or within 24 hours of each other

Suxibuzone and its metabolites are highly protein-bound and may compete with other highly bound drugs (e.g. sulphonamides, warfarin), resulting in increased free pharmacologically active concentrations and potential toxicity — drug compatibility must be closely monitored when adjunctive therapy is required

Concurrent administration of potentially nephrotoxic drugs should be avoided

POM-V Prescription Notice

This product is a Prescription Only Medicine — Veterinary (POM-V). It may only be supplied by a veterinary surgeon or, when prescribed by a veterinary surgeon, by a pharmacist or SQP. A valid veterinary prescription is required before this product can be dispensed.

MA Number: Vm 46037/4006 (Source: VMD Product Information Database — MA holder: Ecuphar Veterinaria S.L.U.)